or anti-I, and is rarely severe. We present an unusual case of a 21-year-old morbidly obese woman with severe, acute CHD due to the rare anti-Pr, who was transferred to our institution from an outside hospital with severe symptomatic anemia. Significant labs were as follows: hemoglobin 4.1 g/dL, retic 18.9%, haptoglobin <8 mg/dL, lactate dehydrogenase 312 U/L, and ferritin 1,115.6 ng/mL (~3x upper limit of reference range). A strong cold autoantibody was identified, and a specimen was sent to a reference lab for further workup. In the meantime, two units of packed red blood cells (PRBC) were ordered for urgent transfusion. One unit of O negative PRBC that was crossmatch compatible using prewarmed plasma was issued on waiver. At the reference lab, a strong cold autoantibody with anti-Pr specificity was confirmed, and underlying alloantibodies were excluded. The warm-washed cells were used to perform the DAT, which showed polyspecific and C3 4+ positivity (IgG was negative). Four additional units of type A positive PRBC that were crossmatch compatible using prewarmed plasma were transfused during her hospitalization (all units were given via blood warmer). The patient was also treated with oral prednisone. Extensive autoimmune and infectious disease (including Monospot and Mycoplasma IgM) workups were negative. The cold agglutinin titer was positive at 1:1,024. The patient was discharged on hospital day six with a hemoglobin stable 8.7 g/dL.
Introduction: Platelet refractoriness is a common problem leading to delays in treatment, increased length of hospital stay, and higher inpatient costs. A 39-year-old woman with a past medical history of insulin-dependent diabetes and hypothyroidism presented with malaise, non-healing mouth ulcer, gum bleeding, hematochezia, and left axillary abscess. She was diagnosed with precursor B-cell acute lymphocytic leukemia. Due to severe thrombocytopenia and need for chemotherapy optimization, the patient received multiple platelet transfusions during her hospitalization. She became refractory, ABO-compatible platelets were transfused without success, and human leukocyte antigen (HLA) antibody testing revealed 65 antibodies. HLA antigen typing was attempted, but the patient's white blood cell count was too low to obtain results, and buccal testing was not available at the institution. Neurosurgery planned for an Ommaya reservoir placement for intrathecal chemotherapy' however, the procedure was delayed due to severe thrombocytopenia (2,000/uL).
Methods:
We contacted the patient's biological sisters and coordinated efforts to have specimens drawn and sent to our institution for HLA typing. The patient's mother had samples drawn on site for genotyping. The patient's father was estranged. Results from genotyping the patient's mother and two sisters allowed us to determine the patient's most probable HLA genotype. Conclusion: We worked closely with our blood centers to obtain HLA-matched platelets with a combination of compatible and least incompatible haplotypes. Neurosurgery required a platelet count of 50,000/uL to perform the procedure. Following the second apheresis unit, the platelet count improved to 54,000/uL with a corrected count increment of 15,600. This case presented a refractory thrombocytopenic patient with antibodies to nearly all HLA antigens, who required an invasive life-saving procedure, and whom we were unable to HLA genotype. Resourcefulness and teamwork facilitated the successful resolution of this challenging clinical problem allowing the patient to have a shorter hospital stay and improved clinical outcome.
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Formation of a Cold Reactive Anti-A1 After Transfusion With A1 Red Blood Cell Units in the Setting of Gross Hemolysis
Jeffrey Petersen, Darshana Jhala, MD; Corporal Michael J. Crescenz VA Medical Center and University of Pennsylvania, Philadelphia
Introduction: Anti-A1 antibodies can be found as a naturally occurring cold IgM antibody in A subgroup patients, but without clinical significance. The presence of anti-A1 in the overwhelming majority of cases should not affect transfusion management or preclude the use of A1 red blood cells (RBCs). It is known that clinically significant warm-reactive anti-A1 that reacts at 37°C can be clinically significant. In a previous case report, the antibody formed only after alloimmunization with donor A1 RBCs. Here, we report a rare case of a cold-reactive anti-A1 antibody that formed as an alloantibody (after multiple transfusions with group A1 RBC units) in a 76-year-old male patient (A subgroup) with history of myelodysplastic syndrome and metastatic carcinoma who presented with hemolytic anemia. Prior to presentation, the patient had previously typed as blood type A without any reverse typing reaction for anti-A; as a result, the patient had been transfused with group A1 RBCs over the course of two weeks. Just four days prior to his admission, the patient had a febrile transfusion reaction associated with his A1 RBC transfusion; at that time, the patient left with a hemoglobin of 8.7 g/dL. Methods: Given his presenting hemoglobin of 6.1 g/dL, transfusion medicine laboratory related testing (ABO © Therapeutic plasma exchange (TPE) is the removal and replacement of a large volume of plasma in order to treat or alleviate symptoms of a particular disease. Through this process, substances such as antibodies, immune complexes, or other pathologic materials are removed, and the volume is restored by a replacement fluid. The American Society of Apheresis (ASFA), in the seventh edition of Guidelines on the Use of Therapeutic Apheresis, has listed hypertriglyceridemia as a Category III indication for plasmapheresis (optimum role of apheresis therapy is not established; decision-making should be individualized). Few cases of prophylactic plasmapheresis for hypertriglyceridemia have been reported in the case literature. Here we present a case from our institution. A 46-year-old man with a history of recurrent pancreatitis secondary to hypertriglyceridemia presented to our hospital with acute abdominal pain. On admission, his triglyceride levels were found to be greater than 5,250 mg/dL. He underwent therapeutic plasmapheresis, with the extracted plasma appearing opaque white in color, and his triglyceride level dropped to 420 mg/ dL, but again increased after discharge. Since this initial presentation, he has undergone weekly therapeutic plasmapheresis with a replacement fluid of 4 L of lactated Ringer solution with 5% albumin, and his triglyceride levels remain elevated with an average value of approximately 2,500 mg/dL. Despite this persistently elevated triglyceride level, he has not had an episode of pancreatitis in two years. We suggest that the use of plasmapheresis should be considered as a treatment option in prophylaxis of recurrent pancreatitis in patients with hypertriglyceridemia.
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The Not So Insignificant Anti-A1 Antibody: Cause of Severe Hemolytic Transfusion Reaction
Kinjal Shah, MD, Bhavesh Delvadia, MLS(ASCP) SBB; Emory University Hospital, Atlanta, GA
Introduction: Anti-A1 antibody found in A2 and A2B patients binds A1 cells. In most cases, anti-A1 is of no clinical significance, reacting well below body temperature, and is merely a laboratory nuisance causing ABO discrepancies. When anti-A1 is active at body temperature, though rare, extensive destruction of A1 cells in vivo can occur and has been documented. Here we report a case of a severe hemolytic transfusion reaction in an A2 patient after transfusion of A1 red cells. Method: Transfusion of three A1 RBC units resulted in a hemoglobin drop from 9.4 to 6.4 g/dL in 48 hours with no identifiable surviving A1 cells, suggesting complete destruction of transfused cells. Post-transfusion sample showed marked icterus, ABO discrepancy in reverse typing, and a negative antibody screen. IRL workup confirmed patient is negative for A1 antigen and has significant anti-A1 titers. Patient successfully received two units of group O RBCs with expected increased in hemoglobin that was sustained. Conclusion: Approximately 80% of individuals in the US with blood group A express A1. Anti-A1 occurs in 1%-8% of A2 individuals and 22%-35% of A2B individuals. A2 patients with an anti-A1 reactive at 37°C should be transfused with group O or A2 RBCs only. A2B patients should receive group O, A2, A2B, or B RBCs. It is not current practice to test A or B cells as part of a routine eluate panel, though one could consider adding them to routine testing methods. Our case highlights that anti-A1 can cause severe hemolytic anemia. This has important implications for transplants because while successful renal transplantation has been reported across the A1/ A2 blood group barrier in the setting of low titer anti-A1 isoagglutinins, more aggressive anti-A1 titer monitoring along with hemolysis labs may be warranted to assess possibility of clinically significant hemolysis. Most cases of methemoglobinemia are acquired, usually due to exposure to drugs/chemicals that cause increased formation of methemoglobin by directly oxidizing
